Jeremy Gowler

Jeremy Gowler is a proven leader in the biotech field, with a focus in vaccines and pharmaceuticals. His experience spans 20 years and a range of responsibilities, including global product commercialization, business development, and clinical trial oversight. He is currently the Chief Executive Officer of Ophirex, Inc., guiding the company’s efforts to develop an affordable, accessible broad-spectrum treatment for snakebite envenoming.

Mr. Gowler launched his pharmaceutical career in 2002 as a medical representative at Novartis. There, he rose through the ranks, taking on increasing responsibilities in marketing, sales, medical affairs and operations in Canada, the US, and Switzerland. He next served as VP, Global Commercial, at the private equity-backed biotechnology company PaxVax in California, which specialized in developing and commercializing specialty human vaccines; and transitioned to VP, Global Commercial – Vaccines Business Unit at Emergent BioSolutions after that company acquired PaxVax. He later joined Sandoz as Global Head of Commercial for the Biopharmaceutical business unit before moving to Invivyd, where he held the positions of Chief Operating Officer, Chief Commercial Officer, and interim Chief Executive Officer before joining Ophirex in 2024.

Mr. Gowler holds a BSc with a double major in Biology and Environmental Studies from the University of Victoria and a Diploma of Technology in Marketing Management from the British Columbia Institute of Technology. He resides with his family in California.